Hypertension Management in Patients with Obesity: 3 Pearls for Primary Care
January 17, 2025

Caissa Troutman, MD, shares 3 key strategies for managing hypertension in patients with obesity in primary care.

Prioritizing Blood-Based CRC Tests May Lead to Higher Costs and Worse Outcomes, Study Finds
January 17, 2025

Annual colorectal cancer screening with FIT was the most cost-effective strategy among patients with low adherence, researchers reported.

Screening Tools For OSA
January 17, 2025

Panelists discuss how validated questionnaires, clinical assessment tools, and overnight monitoring devices can help identify patients at risk for obstructive sleep apnea, though polysomnography remains the gold standard for definitive diagnosis.

Barriers To Diagnosing OSA
January 17, 2025

Panelists discuss how various obstacles impede obstructive sleep apnea diagnosis, including limited access to sleep studies, lack of patient awareness, high costs, long wait times for testing, and inconsistent screening practices among health care providers.

Medicare Part D Phase 2 Price Negotiations Target Semaglutide (Wegovy) Plus 14 More
January 17, 2025

Price negotiations, effective in 2027, cover drugs for diabetes, cancer, COPD, and more, aiming for substantial Medicare savings.

Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial
January 17, 2025

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

FDA Approves First Generic Daily GLP-1 Injection for Type 2 Diabetes: Daily Dose
January 17, 2025

Your daily dose of the clinical news you may have missed.

DEA Amends Telehealth Prescribing Rules, Including Special Registration for Schedule II-V Medications
January 17, 2025

The DEA action includes 3 new telehealth rules that make permanent several flexibilities enacted during the pandemic and also establish new protections for patients.

Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor
January 17, 2025

Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.

Machine Learning Identifies Risk Factors for Severe Cognitive Decline During Menopause
January 16, 2025

The effective approach to identifying risk for the disruptive cognitive issues holds promise for development of early intervention to mitigate decline.